Actelion Posts A 20% Increase In Revenues

Switzerland-based Actelion, Europe's biggest biotech company, achieved a 20% increase in revenues in 2009, to US$1.65bn from US$1.37bn in 2008, aided by the strong sales of its top-selling product Tracleer (bosentan). Net profit figures reached $288mn, a rise of 2% and a good performance given that earnings were impacted by the December 2009 litigation settlement of US$87.0mn in relation to an arbitration proceeding over the licence agreement for the development of Asahi's

To read the full article, please choose one of the following options: